Ono Pharmaceuticals received FDA approval on 14 February 2025 for vimseltinib, a treatment for tenosynovial giant cell tumor (TGCT), which will be sold under the brand name ROMVIMZA. This approval positions Ono in direct competition with fellow Japanese pharmaceutical company Daiichi Sankyo in the TGCT market.
Daiichi's drug, TURALIO, is approved for adult TGCT patients experiencing severe morbidity or functional limitations for whom surgery is not a viable option. In its latest quarterly report for Q3 of the 2024 fiscal year, Daiichi reported a nearly 25% increase in TURALIO sales, reaching ¥5.1 billion (approximately $33.6 million).
Similar to TURA...
